Skip to main content

CHAMPION-AF Patient Selection

Who is a CHAMPION‑AF Patient?

Qualified trial patients must meet all the following criteria.

Patient has documented non-valvular atrial fibrillation (i.e., atrial fibrillation in the absence of moderate or greater mitral stenosis or a mechanical heart valve) who can tolerate OAC and are not necessarily poor candidates for long-term OAC.

✓ Patient has a CHA2DS2‑VASc score of ≥2 for men and ≥3 for women.

Patient is suitable for the protocol defined pharmacologic regimens in both the test and control arms.

Patient or legal representative is able to understand and willing to provide written informed consent to participate in the trial.

Patient is able and willing to return for required follow-up visits and examinations.

  

Engage All Patients

CHAMPION-AF seeks to demonstrate LAAC for stroke risk reduction in a more inclusive population of NVAF patients, representative of females and people of color.

Centers of Medicare and Medicaid Services announced that patients enrolled for the CHAMPION-AF clinical trial may be eligible for reimbursement.

View results from Boston Scientific's audience research study.

  

Resources for Trial Candidates

Direct your trial candidates to the below resources for more information of the CHAMPION-AF clinical trial.
  
Find a Trial Site

Find a Trial Site

Boston Scientific has selected US sites to be CHAMPION-AF investigational centers. If you have a candidate in mind, view the active trial list provided by clinicaltrials.gov, and reach out to a study physician near you to discuss next steps for referral.


WATCHMAN FLX Device Brief Summary

Top